Key facts
- This page summarizes Wendall Wierenga's Form 4 filing for CYTOKINETICS INC (CYTK).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 16 Jul 2025, 17:44.
Wendall Wierenga - 15 Jul 2025 Form 4 Insider Report for CYTOKINETICS INC (CYTK)
- Reporting relationship
- Director
- Issuer ticker
- CYTK
- Reported as of
- 15 Jul 2025
- Net transaction value
- +$6,234
- SEC form
- 4
- Accepted by SEC
- 16 Jul 2025, 17:44:25 UTC
- Prior SEC filing
- 13 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ John O. Faurescu, attorney-in-fact for Dr. Wierenga
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Wendall Wierenga filed Form 4 for CYTOKINETICS INC (CYTK) on 16 Jul 2025.
Change
- Previous filing in this sequence was filed on 13 Jun 2025.
- Current net transaction value: +$6,234.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001235945
Primary reporting owner
WIERENGA WENDALL
- Relationship
- Director
- Address
- 350 OYSTER POINT BLVD, SOUTH SAN FRANCISCO
- Signature
- /s/ John O. Faurescu, attorney-in-fact for Dr. Wierenga
- Signature date
- 16 Jul 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CYTK
transaction
Common Stock
Award
- Transaction value
- $6,234
- Shares
- +164
- Change %
- +0.51%
- Price
- $38.01
- Shares after
- 32,345
- Date
- 15 Jul 2025
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Director equity in lieu of cash retainer program.